With the continuous improvement of living standards in recent years, the Vietnamese people’s demands for healthcare products have increased significantly. Compared with others, Vietnamese acceptance of healthcare products is later than most other countries.
After watching Scott Gottlieb, M.D. of the FDA comments regarding the rebate rule changes and a warning tweet on biosimilars, AbbVie investors are bailing out. But the industry watchers claim that they don’t need to be.
Emergent BioSolutions, Gaithersburg, Maryland-based Biopharmaceutical Company announced that it will invest $50 million for the next three years to expand the manufacturing capacity for its Camden fill-finish in Baltimore facility. By the time the project has been completed in three years, it is expected to add up 60 jobs.
The global biopharmaceutical company revealed its proposal for the new facility two years back when it signed its agreement with German-based construction engineering company M+W, the plant is expected to be 320,000 square feet. The factory will employee about 900 people, which is scheduled to operate in full- fledge by the first half of 2020.
A particular proposal regarding displaying drug prices in TV ads flummoxed pharma marketers and ad agencies following the unveiling of the drug-pricing agenda by President Trump. Marketers have been hounded with the whys and hows of the proposal even as the administration remains firm on its implementation.
Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to SAGE-217 for the treatment of major depressive disorder (MDD). This is the second Breakthrough Therapy designation granted to Sage since 2016.
Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients with unmet medical needs.
AbbVie, a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. , announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated for the management of endometriosis with associated pain.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.